MindMaze Therapeutics Holding SA (SIX: MMTX), today announced that the SwissNeuroRehab Consortium (www.swissneurorehab.ch) has enrolled its first patient in the High-Dose, High-Intensity (HDHI) neurorehabilitation study – Advancing At-Home Reimbursement Strategy in Europe. The study is a multicenter feasibility and implementation project evaluating whether HDHI neurorehabilitation can be delivered sustainably within a continuum-of-care framework. The study is powered by MindMaze’s precision neurotherapeutic platform (including MindMotionGO, Izar, and Companion). The study targets 300 minutes of active training per week, spanning a 4-6 week inpatient phase, an 8-12 week outpatient/home phase, and a follow-up at 15 months from inclusion. Recruitment is active at Lausanne University Hospital (CHUV), Institution de Lavigny, Rehaklinik Valens, Swiss…

SwissNeuroRehab is pleased to announce the launch of a new HES-SO microcertification course, RehabTech – Technology and Neurorehabilitation (2 ECTS), developed as part of the SwissNeuroRehab programme under the sub-project “Education & Training” (SP5). Taking place from 21–23 May 2026 at the Neurorehabilitation Research Center in Lavigny, this course is designed for healthcare professionals and researchers working in rehabilitation and related fields. It offers a unique opportunity to explore cutting-edge topics such as body and space perception, neuroprosthetics, and the integration of health technologies and AI in rehabilitation pathways. The 3-day programme combines lectures, hands-on laboratory sessions, and interdisciplinary workshops, fostering collaboration across professional backgrounds. Registration is open until 1…